Gnant, Michael

Breast cancer

Harbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., Ruddy, K., Tsang, J., & Cardoso, F. (2019) · Nature Reviews Disease Primers

Breast Cancer Treatment StudiesAdvanced Breast Cancer Therapies

Cited by 3,024

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine

Advanced Breast Cancer TherapiesPI3K/AKT/mTOR signaling in cancer

Cited by 2,863

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2

Piccart, M., Hortobagyi, G. N., Campone, M., Pritchard, K. I., Lebrun, F., Ito, Y., Noguchi, S., Perez, A., Rugo, H. S., Deleu, I., et al. (2014) · Annals of Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 574

Toward a Consensus on Centralization in Surgery

Vonlanthen, R., Lodge, P., Barkun, J. S., Farges, O., Rogiers, X., Soreide, K., Kehlet, H., Reynolds, J. V., Käser, S. A., Naredi, P., et al. (2018) · Annals of Surgery

Healthcare Quality and ManagementHealthcare Systems and Practices

Cited by 274

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

Gnant, M., Dueck, A. C., Frantal, S., Martin, M., Burstein, H. J., Greil, R., Fox, P., Wolff, A. C., Chan, A., Winer, E. P., et al. (2022) · Journal of Clinical Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 235

Hypoxia inducible factor-1α correlates with VEGF-C expression and lymphangiogenesis in breast cancer

Schoppmann, S. F., Fenzl, A., Schindl, M., Bachleitner-Hofmann, T., Nagy, K., Gnant, M., Horvat, R., Jakesz, R., & Birner, P. (2006) · Breast Cancer Research and Treatment

Lymphatic System and DiseasesCancer, Hypoxia, and Metabolism

Cited by 106

The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the compliance of ARomatase inhibitors AssessmenT in daily practice through educational approach (CARIATIDE) study

Neven, P., Markopoulos, C., Tanner, M., Marty, M., Kreienberg, R., Atkins, L., Franquet, A., Gnant, M., Neciosup, S., Tesarova, P., et al. (2014) · The Breast

Medication Adherence and ComplianceCancer survivorship and care

Cited by 53

Inflammatory response and oxidative stress during liver resection

Schwarz, C., Fitschek, F., Bar-Or, D., Klaus, D. A., Tudor, B., Fleischmann, E., Roth, G., Tamandl, D., Wekerle, T., Gnant, M., et al. (2017) · PLOS ONE

Antioxidant Activity and Oxidative StressExercise and Physiological Responses

Cited by 47

The 3-60 criteria challenge established predictors of postoperative mortality and enable timely therapeutic intervention after liver resection

Gyoeri, G. P., Pereyra, D., Braunwarth, E., Ammann, M., Jonas, P., Offensperger, F., Klinglmueller, F., Baumgartner, R., Holzer, S., Gnant, M., et al. (2019) · HepatoBiliary Surgery and Nutrition

Hepatocellular Carcinoma Treatment and PrognosisInflammatory Biomarkers in Disease Prognosis

Cited by 20

A phase 3 study to determine the breast cancer risk reducing effect of denosumab in women carrying a germline BRCA1 mutation (BRCA-P Study).

Bhulani, N., Wood, M., Tsai, J., Bedrosian, I., Hopkins, J. O., Brunet, J., Michaelson-Cohen, R., Schmutzler, R. K., Evans, G. D., Gnant, M., et al. (2022) · Journal of Clinical Oncology

BRCA gene mutations in cancerPARP inhibition in cancer therapy

Cited by 10